Actelion CEO Says 120 Patients Died in Lung Drug Study
This article is for subscribers only.
Actelion Ltd., the Swiss drugmaker, said 120 people died in a clinical trial of more than 700 patients involving its experimental medicine macitentan.
The drug is “very unlikely” to show a statistically significant benefit in extending the lives of patients with pulmonary arterial hypertension, though the company is confident the trial will show patients are helped by the product, Chief Executive Officer Jean-Paul Clozel said on a conference call today.